Section 19A and the Special Access Scheme are both routes to medicines that aren't on the ARTG — but they exist for different reasons and are triggered by different people. Here's how hospital pharmacists, procurement teams and pharmaceutical companies can tell which pathway applies, and why the distinction matters for supply planning.

Dear Healthcare Professional, Shortage of ISONIAZID 100mg tablet bottle (AUST R: 13455) Pro Pharmaceuticals Group recognises the importance of supplying essential medicines in Australia and would like to advise you the change in supply status of ISONIAZID 100mg tablet bottle (AUST R: 13455) in Australia. The Australian registered medicine, ISONIAZID 100mg tablet bottle (AUST R: 13455) Active ingredients: isoniazid Dosage form: Tablet, uncoated Sponsor: Arrotex Pharmaceu

Dear Healthcare Professional, Shortage of CYSTAGON mercaptamine (cysteamine) (as bitartrate) 150mg capsule bottle (AUST R: 60452) and alternative supply arrangement under Section 19A of the Therapeutic Goods Act 1989 The Australian registered medicine, CYSTAGON mercaptamine (cysteamine) (as bitartrate) 150mg capsule bottle (AUST R: 60452), sponsored by Alphapharm Pty Ltd, will be in short supply from late June 2026. Pro Pharmaceuticals Group has arranged supply of an alternat

Imipramine 10 mg tablets are currently experiencing a shortage in Australia due to disruption of Tofranil 10 mg supply. Pro Pharmaceuticals Group has received TGA Section 19A approval to import and supply Imipramine HCL Tablets USP 10 mg (Leading Pharma, USA) to support continuity of treatment for patients during this shortage period.

Praziquantel 600 mg tablets USP (Endo, USA) pack approved under TGA Section 19A

Fludarabine Phosphate Injection Section 19A

There is a current shortage of hydralazine (Apresoline) injection in Australia. Pro Pharmaceuticals Group supplies a TGA Section 19A approved alternative.

Dear Healthcare Professional, Pro Pharmaceuticals Group wishes to advise that the Australian registered product TENOFOVIR DISOPROXIL/EMTRICITABINE/EFAVIRENZ Viatris 300/200/600 (AUST R: 280721) is currently in shortage, as listed on the TGA Medicines Shortage Database. To ensure continuity of care, the TGA has granted approval under Section 19A of the Therapeutic Goods Act 1989 for supply of an alternative product: Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Ta

Due to the ongoing shortage of RIFADIN (Rifampicin 300 mg), Pro Pharmaceuticals Group has secured an alternative product from Lupin USA. Approved under TGA Section 19A until 31 March 2026, the product is now available in both 30- and 60-capsule presentations.

Capecitabine 500mg Tablets (Camber USA) are now available in Australia under TGA Section 19A, due to the national shortage of XELABINE. For hospital orders, contact orders@propg.com.au.